National semaglutide audit launched
A nationwide audit has been launched to gather real-world experiences into semaglutide use among people with diabetes.
The online tool has been developed by the Association of British Clinical Diabetologists (ABCD) in a bid to ascertain whether the experience in real clinical use matches the data from phase 3 clinical trials.
Dr Bob Ryder, Clinical Lead and ABCD’s Nationwide Audits, said: “As you will know, the clinical trials with semaglutide suggest that it is more effective than the other GLP-1 receptor agonists that we have to date, and it is now of interest for us to find out to what extent the experience in clinical trials translates into the real world.
“In our previous audits of GLP-1 receptor agonists we have found that much heavier, more poorly controlled patients were treated than in the clinical trials and the impact of the GLP-1 receptor agonist was greater than in the clinical trials when they were used in the real world. It would be particularly interesting to see if the same applies to semaglutide.”
The data submitted in the audit will be used to quantify and analyse a series of questions, such as how much weight loss occurs with semaglutide in real clinical use, what percentage of people achieve both HbA1c reduction and weight loss with the drug and what is the real world experience of progression to insulin treatment?
Non ABCD members are also able to participate in the audit and contributors can use the data to analyse their own findings as well as being available for national analysis.
Anyone who participates will be acknowledged in all papers and presentations from the audit data and biggest contributors will be offered the possibility of being co-authors.
To take part in the audit click here.